RS
BPMC

R Squared’s Blueprint Medicines BPMC Stock Holding History

R Squared’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,766
Closed -$226K – 569
2025
Q2 		$226K Buy
+1,766
New +$183K 0.12% 276
2025
Q1 		– Sell
-590
Closed -$51.5K – 468
2024
Q4 		$51.5K Buy
+590
New +$54K 0.05% 483

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

R Squared's BPMC Position: Q3 2025 in Review

R Squared sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 1,766 shares — an estimated $226K sold.

R Squared first reported a position in BPMC in Q4 2024 and held it in 2 quarters. The position peaked at $226K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • R Squared reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • R Squared sold 1,766 Blueprint Medicines shares in Q3 2025, an estimated $226K.
  • R Squared first reported a position in Blueprint Medicines in Q4 2024 and held it in 2 quarters.
  • R Squared's Blueprint Medicines position peaked at $226K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on R Squared's 13F filing for Q3 2025, filed 12 Nov 2025.